trial · primary record
Androgen Deprivation Therapy (ADT)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 56 |
| Primary completion | 2030-01 |
| Primary endpoint | To determine the cumulative incidence of participants who experience castration resistance, clinical relapse, or death in the 18-month trial period. |
| Registry ID | NCT07904026 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:27.303Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07904026
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.